MX2021008172A - Un ligando de receptor de adenosina a3 para usarse para obtener un efecto de perdida de peso. - Google Patents

Un ligando de receptor de adenosina a3 para usarse para obtener un efecto de perdida de peso.

Info

Publication number
MX2021008172A
MX2021008172A MX2021008172A MX2021008172A MX2021008172A MX 2021008172 A MX2021008172 A MX 2021008172A MX 2021008172 A MX2021008172 A MX 2021008172A MX 2021008172 A MX2021008172 A MX 2021008172A MX 2021008172 A MX2021008172 A MX 2021008172A
Authority
MX
Mexico
Prior art keywords
achieving
subject
adenosine receptor
loss effect
fat loss
Prior art date
Application number
MX2021008172A
Other languages
English (en)
Inventor
Pnina Fishman
Shira Cohen
Motti Farbstein
Inbal Itzhak
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Publication of MX2021008172A publication Critical patent/MX2021008172A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se relaciona con un ligando de receptor de adenosina A3 (A3AR) para usarse en la obtención de por lo menos un efecto de pérdida de grasa que se selecciona de: reducir el peso del sujeto; reducir la masa grasa corporal en el sujeto; tratar obesidad en un sujeto e inhibir la proliferación de adipocitos en un sujeto. La descripción también se relaciona con composiciones farmacéuticas, métodos de tratamiento y kits que comprenden el ligando de A3AR.
MX2021008172A 2019-01-06 2020-01-05 Un ligando de receptor de adenosina a3 para usarse para obtener un efecto de perdida de peso. MX2021008172A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL264112A IL264112A (en) 2019-01-06 2019-01-06 Adenosine a3 receptor ligand for use in lowering adipocyte levels
PCT/IL2020/050011 WO2020141535A1 (en) 2019-01-06 2020-01-05 An a3 adenosine receptor ligand for use for achieving a fat loss effect

Publications (1)

Publication Number Publication Date
MX2021008172A true MX2021008172A (es) 2021-08-11

Family

ID=65656120

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008172A MX2021008172A (es) 2019-01-06 2020-01-05 Un ligando de receptor de adenosina a3 para usarse para obtener un efecto de perdida de peso.

Country Status (11)

Country Link
US (1) US20220079968A1 (es)
EP (1) EP3906034A1 (es)
JP (2) JP2022517753A (es)
KR (1) KR20210113279A (es)
CN (1) CN113543790A (es)
AU (1) AU2020205042A1 (es)
BR (1) BR112021013084A2 (es)
CA (1) CA3126002A1 (es)
IL (2) IL264112A (es)
MX (1) MX2021008172A (es)
WO (1) WO2020141535A1 (es)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443836A (en) 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
DE69428536T2 (de) 1993-07-13 2002-06-06 Nasa A3 -adenosin -rezeptor agonisten
US5688774A (en) 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
WO1997027173A2 (en) 1996-01-24 1997-07-31 Sumitomo Chemical Company, Limited Dihalopropene compounds, their use as insecticides/acaricides and intermediates for their production
US6048865A (en) 1997-07-29 2000-04-11 Medco Research, Inc. N6 -substituted-adenosine-5'-uronamides as adenosine receptor modulator
JP2003517423A (ja) 1997-07-29 2003-05-27 メドコ リサーチ、インコーポレイテッド アデノシンレセプターモジュレーターとしてのｎ６−置換アデノシン−５′−ウロナミド
AU1363699A (en) 1997-10-23 1999-05-10 National Institute Of Health Methods for reducing ischemic injury of the heart via the sequential administ ration of monophosphoryl lipid a and adenosine receptor agents
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
CN101410114B (zh) 2006-01-26 2012-07-04 美国政府卫生与公共服务部 A3腺苷受体别构调节剂
WO2013111132A1 (en) 2012-01-23 2013-08-01 Can-Fite Biopharma Ltd. Treatment of liver conditions
IL242723B (en) 2015-11-23 2019-12-31 Can Fite Biopharma Ltd A3 adenosine receptor ligand for the treatment of ectopic fat accumulation
KR101881441B1 (ko) * 2017-01-20 2018-07-24 서울대학교산학협력단 다중 약리단 특성에 기반한 비정상적 아디포넥틴 관련 질환 치료용 조성물

Also Published As

Publication number Publication date
BR112021013084A2 (pt) 2021-09-21
US20220079968A1 (en) 2022-03-17
WO2020141535A1 (en) 2020-07-09
JP2023100928A (ja) 2023-07-19
IL264112A (en) 2020-07-30
IL284463A (en) 2021-08-31
KR20210113279A (ko) 2021-09-15
CN113543790A (zh) 2021-10-22
CA3126002A1 (en) 2020-07-09
AU2020205042A1 (en) 2021-07-15
JP2022517753A (ja) 2022-03-10
EP3906034A1 (en) 2021-11-10

Similar Documents

Publication Publication Date Title
PH12020551923A1 (en) Methods and compositions for treating cancer
MX2022004101A (es) Composiciones de oligonucleotidos y metodos de uso de las mismas.
PH12020551251A1 (en) Jak1 pathway inhibitors for the treatment of cytokine-related disorders
MX2022001075A (es) Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
MX2021002998A (es) Compuestos de triazolo-pirimidina y usos de los mismos.
PH12020551038A1 (en) Compositions comprising co-selected microbiota and methods for use thereof
MX2021002180A (es) Composiciones de inhibidores del receptor de quimiocina c-x-c tipo 4 (cxcr4) y metodos de preparacion y uso.
MX2019003363A (es) Composiciones farmaceuticas para usarse en la terapia de la blefaritis.
MX2021004708A (es) Metodos y composiciones para tratamiento de presbicia, midriasis y otros trastornos oculares.
MY183462A (en) A pharmaceutical composition for anaemia
MX2021001902A (es) Anticuerpos que se unen a histona 2a y/o 4 citrulinada.
CR20220329A (es) Anticuerpos anti–mertk y metodos de uso de los mismos
PH12020551071A1 (en) Compositions and methods for treating retinal disorders
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
MX2020008991A (es) Metodos para alterar la composicion corporal.
MX2021008727A (es) Tratamiento de la hepatotoxicidad.
IL288953A (en) Pharmaceutical compounds, kits and methods for the treatment of cancerous tumors
PH12021551365A1 (en) Compositions and methods for treating and preventing amyotrophic lateral sclerosis
MX2021008172A (es) Un ligando de receptor de adenosina a3 para usarse para obtener un efecto de perdida de peso.
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
MX2019007041A (es) Metodos y composiciones para tratar la enfermedad de parkinson.
MX2022005250A (es) Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b.
WO2019190927A3 (en) Splice-switching oligonucleotides and methods of use
MX2020011377A (es) Metodos y composiciones para el tratamiento de urticaria cronica.
NZ760873A (en) Methods of treating myelodysplastic syndrome